EUVIMEDEUVIMED entdecken
Crossref

Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: A pilot study

T Krechler, M Jachymova, M Pavlikova, M Vecka, M Zeman, Z Krska, T Svestka, A Zak

Neoplasma · 2009

DOI: 10.4149/neo_2009_01_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neoplasma, 2009. Verfasst von T Krechler und 7 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Medicine, 1st Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic. krechler@vfn.cz. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PC) is one of the most frequent gastrointestinal malignancies with extremely poor prognosis. In spite of a relative low incidence of PC, in comparison with other cancers, PC is the fourth leading cause of cancer death in USA in both sexes. The available data clearly suggest that diabetes mellitus (DM) can be both a long-standing cause of PC and an early manifestation of the disease. Besides of DM, insulin resistance and high insulin levels are linked as well with increased cancer risk, including PC. The variable number of tandem repeats (VNTR) locus upstream of the insulin gene (INS) regulates insulin expression and has been associated with susceptibility to many diseases including DM. It is known that there is nearly complete linkage disequilibrium of the insulin variable tandem of repeats (INS-VNTR) alleles I/III with neighboring -23 HphI A/T single nucleotide polymorphism (SNP) in Caucasians. Therefore, we have studied the association between SNP of -23HphI in promoter of INS with PC, DM Type 2 (2TDM) and healthy controls. In this study we investigated 153 subjects (86 M/67 F); 51 patients with newly-diagnosed PC (31 M/20 F), 45 patients with 2TDM (29 M/16 F) and 57 healthy control subjects (26 M/31 F). The polymorphism of -23HphI (A/T) in the promoter of INS was determined by the combination of polymerase chain reaction (PCR) with the restriction fragment length polymorphism (RFLP) methods. The results obtained by the PCR-RFLP analyses of SNP -23HphI were confirmed by a direct studied locus sequencing of the genomic DNA. The frequency of abnormal glucose metabolism (both DM and impaired fasting glucose) was 88 % (45/51) in PC group. The AA genotype in SNP -23HphI was more prevalent (67 % vs. 47 %; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseAgedDiabetes Mellitus, Type 2FemaleHumansInsulinMaleMiddle AgedMinisatellite RepeatsNeoplasm StagingPancreatic NeoplasmsPilot ProjectsPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single NucleotidePromoter Regions, Genetic

Substanzen

Insulin

Autor:innen und Institutionen

  • 4th Department of Medicine, 1st Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic. krechler@vfn.cz

Zitieren

APA

Krechler, T., Jachymova, M., Pavlikova, M., Vecka, M., Zeman, M., Krska, Z., Svestka, T., & Zak, A. (2009). Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: A pilot study. Neoplasma. https://doi.org/10.4149/neo_2009_01_26

Vancouver

Krechler T, Jachymova M, Pavlikova M, Vecka M, Zeman M, Krska Z, et al. Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: A pilot study. Neoplasma. 2009. doi:10.4149/neo_2009_01_26

BibTeX
@article{Krechler2009,
  author = {Krechler, T and Jachymova, M and Pavlikova, M and Vecka, M and Zeman, M and Krska, Z and Svestka, T and Zak, A},
  title = {Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: A pilot study},
  journal = {Neoplasma},
  year = {2009},
  doi = {10.4149/neo_2009_01_26}
}
Kostenlos starten →